HIV Infections Clinical Trial
Official title:
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
Verified date | June 2018 |
Source | Universidade Federal do Rio Grande do Norte |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Among the many changes associated with the impact of HIV and the long-term use of antiretroviral therapy, metabolics are important because they are important risk factors for the development of cardiovascular diseases. The objective of the present study is to evaluate the effect of the supplementation of curcumin, on the oxidation of resting energetic substrates in HIV / AIDS patients. The sample will be composed of adults living with HIV / AIDS on antiretroviral therapy for at least 6 months. Supplements will be made separately for 30 days and will be evaluated before and after the intervention the following parameters: body composition, energy metabolism, biochemical parameters and a structured anamnesis. Food consumption and the level of physical activity of the volunteers will be controlled.
Status | Completed |
Enrollment | 20 |
Est. completion date | December 5, 2017 |
Est. primary completion date | October 24, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Antiretroviral therapy has been available for at least 6 months, aged 18 years or over. Exclusion Criteria: - Individuals with endocrine and pregnant disorders will be excluded. |
Country | Name | City | State |
---|---|---|---|
Brazil | Universidade Federal Do Rio Grande Do Norte | Natal | RN |
Lead Sponsor | Collaborator |
---|---|
Universidade Federal do Rio Grande do Norte |
Brazil,
Kosmiski LA, Bessesen DH, Stotz SA, Koeppe JR, Horton TJ. Short-term energy restriction reduces resting energy expenditure in patients with HIV lipodystrophy and hypermetabolism. Metabolism. 2007 Feb;56(2):289-95. — View Citation
Pannacciulli N, Salbe AD, Ortega E, Venti CA, Bogardus C, Krakoff J. The 24-h carbohydrate oxidation rate in a human respiratory chamber predicts ad libitum food intake. Am J Clin Nutr. 2007 Sep;86(3):625-32. — View Citation
Vassimon HS, de Paula FJ, Machado AA, Monteiro JP, Jordão AA Jr. Hypermetabolism and altered substrate oxidation in HIV-infected patients with lipodystrophy. Nutrition. 2012 Sep;28(9):912-6. doi: 10.1016/j.nut.2011.12.010. Epub 2012 Apr 13. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Body composition | The body composition will be evaluated by the indirect method of Dual Energy Radiological Absortometry (DEXA) through the Prodigy® Lunar Bone Densitometry apparatus. | 10 DAYS | |
Primary | The oxidation of energetic substrates evaluation at rest | The oxidation of energetic substrates evaluation at rest will be performed by indirect calorimetry, a gold standard method for the measurement of energy expenditure, making feasible through the breath by breath technique, weightings to quantify the Caloric expenditure from oxidation fats and carbohydrates. Evaluation will not offer any discomfort since the volunteer will lie flat without moving with a mask fixed on his face, which picks up the breathed and expired gases to be measured by the Respiratory Analyzer - Metalyzer 3B-MICROMED®. To determine oxidation of energetic substrates, subjects will be instructed to sleep approximately for 8 hours the night before, to fast for 12 hours, not to exercise and not to drink caffeinated beverages or alcohol in the 24 hours before the test. Such care should be taken in order to reduce the influence of the thermal effect of food and physical activity on resting metabolism |
10 DAYS | |
Secondary | Energy expenditure at rest | The evaluation of resting energy expenditure will be performed by indirect calorimetry, a gold standard method for the measurement of energy expenditure, making feasible through the breath by breath technique, weightings to quantify the energy expenditure of rest. Evaluation will not offer any discomfort since the volunteer will lie flat without moving with a mask fixed on his face, which picks up the breathed and expired gases to be measured by the Respiratory Analyzer - Metalyzer 3B-MICROMED®. To determine resting energy expenditure, subjects will be instructed to sleep approximately for 8 hours the night before, to fast for 12 hours, not to exercise and not to drink caffeinated beverages or alcohol in the 24 hours before the test. Such care should be taken in order to reduce the influence of the thermal effect of food and physical activity on resting metabolism. |
10 DAYS | |
Secondary | The glycemia evaluation | Individuals will undergo a peripheral vein puncture in the morning after fasting from 12 to 14 h. Blood will be collected in 30 ml of blood in vacuum containment tubes without anticoagulant; Tubes will be identified with a different registration number for each participant.In order to obtain the serum, the blood samples will be centrifuged for 10 min at 2500 rpm at room temperature. Serum levels of glucose will be performed by enzyme-colorimetric assays using Labtest Diagnostic kits suitable for the RA-50 semi-automated biochemical analyzer (Bayer Diagnostics Chemistry System, Dublin). | 10 DAYS | |
Secondary | The insulin evaluation | Individuals will undergo a peripheral vein puncture in the morning after fasting from 12 to 14 h. Blood will be collected in 30 ml of blood in vacuum containment tubes without anticoagulant; Tubes will be identified with a different registration number for each participant.In order to obtain the serum, the blood samples will be centrifuged for 10 min at 2500 rpm at room temperature.Serum levels of insulin will be performed by enzyme-colorimetric assays using Labtest Diagnostic kits suitable for the RA-50 semi-automated biochemical analyzer (Bayer Diagnostics Chemistry System, Dublin). | 10 DAYS | |
Secondary | The total cholesterol evalution | Individuals will undergo a peripheral vein puncture in the morning after fasting from 12 to 14 h. Blood will be collected in 30 ml of blood in vacuum containment tubes without anticoagulant; Tubes will be identified with a different registration number for each participant.In order to obtain the serum, the blood samples will be centrifuged for 10 min at 2500 rpm at room temperature.Serum levels of total cholesterol will be performed by enzyme-colorimetric assays using Labtest Diagnostic kits suitable for the RA-50 semi-automated biochemical analyzer (Bayer Diagnostics Chemistry System, Dublin). | 10 DAYS | |
Secondary | The LDL cholesterol evalution | Individuals will undergo a peripheral vein puncture in the morning after fasting from 12 to 14 h. Blood will be collected in 30 ml of blood in vacuum containment tubes without anticoagulant; Tubes will be identified with a different registration number for each participant.In order to obtain the serum, the blood samples will be centrifuged for 10 min at 2500 rpm at room temperature.Serum levels of LDL cholesterol will be performed by enzyme-colorimetric assays using Labtest Diagnostic kits suitable for the RA-50 semi-automated biochemical analyzer (Bayer Diagnostics Chemistry System, Dublin). | 10 DAYS | |
Secondary | The HDL cholesterol evalution | Individuals will undergo a peripheral vein puncture in the morning after fasting from 12 to 14 h. Blood will be collected in 30 ml of blood in vacuum containment tubes without anticoagulant; Tubes will be identified with a different registration number for each participant.In order to obtain the serum, the blood samples will be centrifuged for 10 min at 2500 rpm at room temperature.Serum levels of HDL cholesterol will be performed by enzyme-colorimetric assays using Labtest Diagnostic kits suitable for the RA-50 semi-automated biochemical analyzer (Bayer Diagnostics Chemistry System, Dublin). | 10 DAYS | |
Secondary | The triglycerides evalution | Individuals will undergo a peripheral vein puncture in the morning after fasting from 12 to 14 h. Blood will be collected in 30 ml of blood in vacuum containment tubes without anticoagulant; Tubes will be identified with a different registration number for each participant.In order to obtain the serum, the blood samples will be centrifuged for 10 min at 2500 rpm at room temperature.Serum levels of triglycerides will be performed by enzyme-colorimetric assays using Labtest Diagnostic kits suitable for the RA-50 semi-automated biochemical analyzer (Bayer Diagnostics Chemistry System, Dublin). | 10 DAYS | |
Secondary | The inflammatory markers evalution | Individuals will undergo a peripheral vein puncture in the morning after fasting from 12 to 14 h. Blood will be collected in 30 ml of blood in vacuum containment tubes without anticoagulant; Tubes will be identified with a different registration number for each participant.In order to obtain the serum, the blood samples will be centrifuged for 10 min at 2500 rpm at room temperature. | 10 DAYS | |
Secondary | The oxidative stress markers evalution | Individuals will undergo a peripheral vein puncture in the morning after fasting from 12 to 14 h. Blood will be collected in 30 ml of blood in vacuum containment tubes without anticoagulant; Tubes will be identified with a different registration number for each participant.In order to obtain the serum, the blood samples will be centrifuged for 10 min at 2500 rpm at room temperature. | 10 DAYS |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 | |
Completed |
NCT01968551 -
Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
|
Phase 3 |